PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Flu season prep, complicated by COVID-19, starts early this year

Thu, 13th Aug 2020 13:35

(Adds AstraZeneca details on FluMist vaccine)

By Carl O'Donnell

Aug 13 (Reuters) - Healthcare providers, including CVS
Health Corp, are kicking off flu vaccinations early,
ordering extra shots and aiming to add tests that check for both
the annual flu and COVID-19, pharmacy executives and experts
told Reuters.

Flu vaccination for the fall has taken on increased urgency
because of the potential for serious complications if patients
contract both viruses at once.

Vaccine makers will provide nearly 200 million flu vaccines
to the United States this year, potentially 20% more than is
typical, said LJ Tan, chief strategy officer for the
Immunization Action Coalition, a nonprofit that promotes
vaccination.

CVS expects to more than double the number of flu shots it
provides to around 18 million people and Walgreens Boots
Alliance Inc is stockpiling extra vaccines, the
companies told Reuters.

Drugmaker AstraZeneca Plc on Thursday announced its
first shipment of its FluMist vaccine in the U.S. and said it
has increased production of doses in the U.S. by over 25% more
than previously planned.

Failure to inoculate for the flu could also strain the
United States COVID-19 testing capacity, which is still below
the 6-10 million daily tests needed, Reuters has reported.

"If we can eliminate the dynamic of people getting symptoms
and their first reaction is ‘is this the seasonal flu or is this
COVID,’ it can take demand off of COVID-19 testing," CVS Chief
Executive Larry Merlo told Reuters.

Merlo added that CVS is working to obtain tests that screen
for both viruses simultaneously. U.S. regulators approved a
joint COVID-19 and flu test in July.

The same people who are most vulnerable to risks from
COVID-19, such as the elderly and those with respiratory
conditions, are also at greatest risk for the flu, Tan added.

The U.S. healthcare system is already expected to be
strained in the fall by a resurgence in COVID-19. The Institute
for Health Metrics and Evaluation is anticipating an uptick in
COVID-19 cases in the coming months, resulting in around 300,000
total deaths by December, up from the current figure of roughly
160,000, and a nearly 75% increase in hospitalizations.

There is evidence that social distancing measures for
COVID-19 reduce the transmission rate of the flu as well,
according to the U.S. Centers for Disease Control and
Prevention, meaning that continued measures in the U.S. could
potentially slow flu transmission this season.

However, efforts to inoculate patients for the flu could be
complicated by the need to safeguard patients and healthcare
workers from COVID-19.

"If a patient has a fever or other symptoms associated with
illness, they will be referred to their healthcare provider and
immunizations will be deferred," a Walgreens spokeswoman told
Reuters.

CVS plans to begin inoculating patients earlier than usual -
possibly by the end of this month - to get a jump start on
preparing for this year's flu season, which usually starts
around October.

However, studies show there is a risk that getting
inoculated against the flu too early can leave a patient
vulnerable to contracting the virus later on in winter, if the
shot wears off.

Other physicians are also starting this month, though it
will still take months to fully distribute all the needed
inoculations, Tan said.

The flu vaccine "comes out over time so you want to make
sure people continue to seek flu vaccines" through Thanksgiving
and beyond, Tan said.
(Reporting by Carl O'Donnell; Editing by Peter Henderson,
Aurora Ellis and Bernadette Baum)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.